Trade Names:Cephalexin- Tablets 250 mg- Tablets 500 mg- Powder for oral suspension 125 mg per 5 mL- Powder for oral suspension 250 mg per 5 mL
Trade Names:Keflex- Capsules 250 mg- Capsules 500 mg- Capsules 750 mgAPO-Cephalex (Canada)Novo-Lexin (Canada)Nu-Cephalex (Canada)
Inhibits mucopeptide synthesis in bacterial cell wall.
Cephalexin is rapidly absorbed. C max is about 9 to 32 mcg/mL (250 mg to 1 g doses). T max is 1 h.
Cephalexin is 10% protein bound.
More than 90% is excreted unchanged in the urine within 8 h. The half-life is 50 to 80 min.
Treatment of infections of respiratory tract, urinary tract, skin and skin structures, and bone; treatment of otitis media caused by susceptible strains of specific microorganisms.
Hypersensitivity to cephalosporins.
PO 1 to 4 g/day in divided doses (max, 4 g/day).Children
PO 25 to 50 mg/kg/day in divided doses.
Oral suspension is stable up to 14 days after reconstitution when refrigerated. Store capsules and tablets at room temperature (59° to 86°F).
May increase metformin plasma C max and AUC.Probenecid
Inhibition of renal excretion of cephalexin.
May cause false-positive urine glucose test results with Benedict solution, Fehling solution, or Clinitest tablets, but not with enzyme-based tests (eg, Clinistix , Tes-Tape ); false-positive test results for proteinuria with acid and denaturization-precipitation tests; false-positive direct Coombs test results in certain patients (eg, those with azotemia); false elevations in urinary 17-ketosteroid values.
Agitation, confusion, dizziness, fatigue, hallucinations, headache.
Anorexia; abdominal pain or cramps; colitis, including pseudomembranous colitis; diarrhea; dyspepsia; flatulence; gastritis; nausea; vomiting.
Genital moniliasis, genital pruritus, reversible interstitial nephritis, vaginitis and vaginal discharge.
Eosinophilia, hemolytic anemia, neutropenia, thrombocytopenia.
Cholestatic jaundice, elevated AST and ALT, hepatitis.
Arthralgia, arthritis, joint disorder.
Anal pruritus; anaphylaxis; candidal overgrowth; hypersensitivity, including rash, Stevens-Johnson syndrome, angioedema, erythema multiforme, toxic epidermal necrolysis, and urticaria.
Monitor patient's response to therapy. Instruct patient to notify health care provider if infection does not appear to improve or worsens. Monitor prothrombin time in patients on anticoagulants. Monitor patient for adverse reactions and signs of superinfection.
Category B .
Excreted in breast milk.
Cephalosporins may accumulate in newborns.
Reactions range from mild to life-threatening. Administer drug with caution to penicillin-sensitive patients because of possible cross-reactivity.
Use drug with caution in patients with renal function impairment. Dosage adjustment based on renal function may be required.
May result in bacterial or fungal overgrowth of nonsusceptible microorganisms.
Use with caution, particularly colitis.
Consider in patients in whom diarrhea develops.
Diarrhea, epigastric distress, hematuria, nausea, vomiting.
Copyright © 2009 Wolters Kluwer Health.